<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03315403</url>
  </required_header>
  <id_info>
    <org_study_id>63200</org_study_id>
    <nct_id>NCT03315403</nct_id>
  </id_info>
  <brief_title>Quantitative Polymerase Chain Reaction for Improved Detection of Pneumococci in CAP &quot;CAPTAIN&quot;</brief_title>
  <acronym>CAPTAIN</acronym>
  <official_title>Community-Acquired Pneumonia: lytA TArgeted Real Time Quantitative Polymerase chaIN Reaction for Improved Detection of Pneumococci (CAPTAIN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Center Alkmaar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Center Alkmaar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the added diagnostic value of a quantitative&#xD;
      polymerase chain reaction targeting the lytA gene in detecting pneumococci in patients with&#xD;
      community-acquired pneumonia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>qPCR diagnosed pneumococcal pneumonia</measure>
    <time_frame>1 day, day of inclusion</time_frame>
    <description>Occurrence of qPCR proven pneumococcal pneumonia (CAP with S. pneumoniae detected by qPCR in at least one of the samples with a positive lytA qPCR and a DNA copy number above the determined cut-off value) using the cut-off value in at least one of the specimens at inclusion. The cut-off value will be determined in this study, see secondary objective.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pneumococcal pneumonia with usual tests</measure>
    <time_frame>1 day, day of inclusion</time_frame>
    <description>Occurrence of pneumococcal pneumonia proven by at least one of the routine microbiological tests (urine antigen test, blood culture and/or sputum culture). The difference between outcome measure 1 and 2 is the added diagnostic value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of DNA copies of S. pneumoniae in all lytA qPCR positive study subjects</measure>
    <time_frame>1 day, day of inclusion</time_frame>
    <description>The number of DNA copies of every study subject with a positive qPCR will be determined. The optimal cut-off value will be determined to distinguish between colonisation and infection by comparing the number of DNA copies of controls with a positive lytA PCR and patients with a pneumococcal pneumonia proven by routine microbiological tests. This cut-off value will be used for outcome measure 1 to determine the amount of patients with an qPCR proven pneumococcal pneumonia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of positive lytA qPCR at 30 days after inclusion in CAP patients</measure>
    <time_frame>30 days</time_frame>
    <description>Occurrence of positive lytA qPCR at 30 days after inclusion in CAP patients in the different samples: oropharynx, nasopharynx, saliva and sputum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CURB-65 scores</measure>
    <time_frame>1 day, day of inclusion</time_frame>
    <description>CURB-65 scores will be determined in CAP patients at moment of inclusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procalcitonin</measure>
    <time_frame>1 day, day of inclusion</time_frame>
    <description>Procalcitonin levels will be determined in CAP patients at moment of inclusion.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">1061</enrollment>
  <condition>Pneumonia, Pneumococcal</condition>
  <condition>Community-acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Patients with CAP</arm_group_label>
    <description>Patients with a diagnosis of radiographically-confirmed CAP at the emergency department will undergo the usual diagnostics. For the study an extra nasopharynx sample, saliva sample and blood sample will be collected.&#xD;
A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Related controls</arm_group_label>
    <description>Of related controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.&#xD;
A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unrelated controls</arm_group_label>
    <description>Of unrelated controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.&#xD;
A questionnaire will be filled in. LytA PCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with stable COPD</arm_group_label>
    <description>Of stable COPD patients a nasopharynx sample, oropharynx sample and saliva sample will be collected. And if available also a sputum sample.&#xD;
A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with exacerbation of COPD</arm_group_label>
    <description>Of patients with a diagnosis of an exacerbation of COPD at the emergency department a nasopharynx sample, oropharynx sample and saliva sample will be collected apart from the usual diagnostics. If available also a sputum sample will be collected.&#xD;
A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>LytA targeted quantitative polymerase chain reaction (qPCR)</intervention_name>
    <description>LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)</description>
    <arm_group_label>Patients with CAP</arm_group_label>
    <arm_group_label>Patients with exacerbation of COPD</arm_group_label>
    <arm_group_label>Patients with stable COPD</arm_group_label>
    <arm_group_label>Related controls</arm_group_label>
    <arm_group_label>Unrelated controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Collection of nasopharynx, oropharynx, saliva, sputum and blood.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient group: Adult patients ≥18 years with diagnosis of CAP at the emergency department&#xD;
        (ED).&#xD;
&#xD;
        Control groups (without CAP):&#xD;
&#xD;
          -  Related controls (inclusion at ED)&#xD;
&#xD;
          -  Unrelated healthy adults (inclusion at an outpatient preoperative appointment for any&#xD;
             elective surgery)&#xD;
&#xD;
          -  Stable COPD patients (inclusion at outpatient clinic for pulmonary diseases)&#xD;
&#xD;
          -  COPD patients with an AECOPD (inclusion at ED)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients:&#xD;
&#xD;
          -  Age 18 years or above;&#xD;
&#xD;
          -  Presentation at the emergency department (ED);&#xD;
&#xD;
          -  Working diagnosis of CAP at the ED with the presence of at least two of the following&#xD;
             criteria:&#xD;
&#xD;
               1. New or worsened coughing;&#xD;
&#xD;
               2. Production of purulent sputum or change in sputum colour;&#xD;
&#xD;
               3. Temperature &gt;38.0 ⁰C or ≤36.0 ⁰C (tympanic);&#xD;
&#xD;
               4. Auscultatory findings consistent with pneumonia, including rales, evidence of&#xD;
                  pulmonary consolidation (dullness on percussion, bronchial breath sounds, rales,&#xD;
                  or egophony), or both;&#xD;
&#xD;
               5. White blood cell count of &gt;10x10^9 cells/L or &lt;4x10^9 cells/L or &gt;15% bands;&#xD;
&#xD;
               6. C-reactive protein level ≥30mg/L;&#xD;
&#xD;
               7. Dyspnea, tachypnea, (&gt;20 breaths per minute), or hypoxemia (arterial pO2 &lt;60mmHg&#xD;
                  or peripheral O2 saturation &lt;90%).&#xD;
&#xD;
          -  New consolidation(s) on the chest radiograph or computed tomography (CT);&#xD;
&#xD;
          -  No other explanation for the signs and symptoms;&#xD;
&#xD;
        Control group 1 - Related controls&#xD;
&#xD;
          -  Being aged 18 years or above;&#xD;
&#xD;
          -  Close relative of the patient: relative defined as living in the same house as the CAP&#xD;
             patient or daily contact;&#xD;
&#xD;
          -  Is at the hospital at the moment of inclusion of the CAP patient or is willing to come&#xD;
             for testing within 7 days;&#xD;
&#xD;
        Control group 2 - Unrelated healthy individuals&#xD;
&#xD;
          -  Being aged 18 years or above;&#xD;
&#xD;
          -  Subject with a preoperative appointment with the anaesthiologist for a planned&#xD;
             surgical procedure;&#xD;
&#xD;
          -  Age matched to a included CAP patient (+-10 years);&#xD;
&#xD;
          -  Time matched to a included CAP patient (up to 14 days after inclusion of the CAP&#xD;
             patient);&#xD;
&#xD;
          -  Gender matched to a included CAP patient.&#xD;
&#xD;
        Control group 3 - Patients with stable COPD&#xD;
&#xD;
          -  Being aged 18 years or above;&#xD;
&#xD;
          -  Diagnosis of COPD confirmed with spirometry (GOLD criteria 2017)(76);&#xD;
&#xD;
          -  Stable disease.&#xD;
&#xD;
        Control group 4 - Patients with exacerbation of COPD&#xD;
&#xD;
          -  Being aged 18 years or above;&#xD;
&#xD;
          -  Diagnosis of COPD confirmed with spirometry (GOLD criteria 2017)(76);&#xD;
&#xD;
          -  Diagnosis of exacerbation of COPD: defined as an acute event characterised by a&#xD;
             worsening of the patient's respiratory symptoms that is beyond normal day-to-day&#xD;
             variations and leads to a change in medication (76).&#xD;
&#xD;
          -  Presentation at emergency department with the suspicion of an exacerbation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        In general:&#xD;
&#xD;
          -  Recent pneumonia (&lt; 1 month) or pneumonia in last 3 months with known pneumococcal&#xD;
             aetiology with one of current diagnostics;&#xD;
&#xD;
          -  Was included in the study group before;&#xD;
&#xD;
          -  Not capable of understanding information needed to sign informed consent.&#xD;
&#xD;
        Patients:&#xD;
&#xD;
          -  Aspiration pneumonia;&#xD;
&#xD;
          -  Hospitalisation for two or more days in the last 14 days;&#xD;
&#xD;
          -  History of cystic fibrosis.&#xD;
&#xD;
        For all control groups:&#xD;
&#xD;
          -  Fits inclusion criteria for patient group;&#xD;
&#xD;
          -  Present or recent hospitalisation (14 days);&#xD;
&#xD;
          -  Fits inclusion criteria for patient group;&#xD;
&#xD;
          -  Use of antibiotics in the last 14 days, including maintenance antibiotic therapy.&#xD;
&#xD;
        Control group 1 and 2 - Related healthy controls and unrelated healthy individuals&#xD;
&#xD;
          -  Active infectious respiratory complaints defined as defined as two or more respiratory&#xD;
             symptoms (cough, nasal congestion, runny nose, sore throat or sneezes);&#xD;
&#xD;
          -  Temperature &gt;38.0 ⁰C;&#xD;
&#xD;
          -  Fits inclusion criteria for control group 3 or 4;&#xD;
&#xD;
          -  Chronic pulmonary disease: COPD, asthma, cystic fibrosis, bronchiectasis.&#xD;
&#xD;
        Control group 3 - Patients with stable COPD&#xD;
&#xD;
          -  Temperature &gt;38.0 ⁰C;&#xD;
&#xD;
          -  Stable disease;&#xD;
&#xD;
          -  Fits inclusion criteria for control group 4;&#xD;
&#xD;
          -  Recent exacerbation (&lt;1 month) defined as increased respiratory symptoms with need of&#xD;
             antibiotic and/or corticosteroid therapy;&#xD;
&#xD;
          -  History of cystic fibrosis.&#xD;
&#xD;
        Control group 4 - Patients with exacerbation of COPD&#xD;
&#xD;
          -  Current pneumonia;&#xD;
&#xD;
          -  Recent exacerbation (&lt;1 month) defined as increased respiratory symptoms with need of&#xD;
             antibiotic and/or corticosteroid therapy;&#xD;
&#xD;
          -  Fits inclusion criteria for control group 3;&#xD;
&#xD;
          -  History of cystic fibrosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim Boersma, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Noordwest Ziekenhuisgroep</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nienke Paternotte, MD</last_name>
    <phone>0031725484444</phone>
    <phone_ext>5314</phone_ext>
    <email>n.paternotte@nwz.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Spaarne Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominic Snijders, Dr. MD.</last_name>
      <email>dsnijders@spaarnegasthuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Noordwest Ziekenhuisgroep</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nienke Paternotte, MD</last_name>
      <phone>0031725484444</phone>
      <phone_ext>5314</phone_ext>
      <email>n.paternotte@nwz.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 3, 2017</study_first_submitted>
  <study_first_submitted_qc>October 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical Center Alkmaar</investigator_affiliation>
    <investigator_full_name>W.G.Boersma</investigator_full_name>
    <investigator_title>MD. PhD. Pulmonologist</investigator_title>
  </responsible_party>
  <keyword>quantitative polymerase chain reaction</keyword>
  <keyword>qPCR</keyword>
  <keyword>autolysin</keyword>
  <keyword>lytA</keyword>
  <keyword>Pneumococcal pneumonia</keyword>
  <keyword>Diagnostics</keyword>
  <keyword>Community-acquired Pneumonia</keyword>
  <keyword>Antibiotic resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

